Introduction {#Sec1}
============

Colorectal canceris one of the leading malignanciesand the fifth most frequent cause of cancer-related deathworldwide^[@CR1],[@CR2]^. Approximately 20--25% of patients have synchronous liver metastaseswhile being diagnosed, and a further 35 to 45% of patients will develop metachronoushepatic metastases following the removal ofprimary tumor^[@CR3]^. The mean survival for patients with untreated colorectal liver metastasis (CRLM) has been found to range from 6--13 months^[@CR4],[@CR5]^. Thus, the management of CRLM remains clinically challenging.

Hepatic resection is the mainstay of treatmentand potentially curative therapy for CRLM,with reported 5-year survival of 30--50%^[@CR4]--[@CR6]^. However, the recurrence rate has been reported to be high(60--80%)and only 16% of these patients remain disease free for 10 years after hepatectomy^[@CR7]^. Some studies have therefore tried to find probable prognostic predictors affecting CRLM receiving resection, including elder age, number and size of hepatic lesions, the primary lymph node status and preoperative anemia^[@CR8],[@CR9]^. This issue should be further clarified with the advances of new chemotherapeutic regimensand target therapy as well as the operative technique.

Sarcopenia is a syndrome characterized by loss of muscle mass, function and strength that is quantifiable using cross sectional imaging by measurement of psoas area and the muscle's density^[@CR10],[@CR11]^. Recently, there is increasing evidence that sarcopeniais an important prognostic factor of frailty, mortality, and worse surgical outcomes^[@CR12]^. Sarcopenia has been reported to affect not only operative complications^[@CR13]^, but also cancer-specific outcomes following hepatic resection^[@CR14],[@CR15]^, colectomy^[@CR16]^, and pancreatic resection^[@CR17]^. Until now, the role of sarcopenia in the long-term survival of patients with CRLMafter partial hepatectomy remains limited^[@CR15],[@CR18]^. Thus, we conducted this study to clarify this issue.

Materials and methods {#Sec2}
=====================

Study population {#Sec3}
----------------

Between July 2008 and July 2018, 193 consecutive patients who underwent curative intent surgery for CRLM were identified from a single tertiary center. Of them, 11 patients without available abdominal computed tomography (CT) images within 30 days of surgerywere excluded. Preoperative workup included triple phase-contrast enhanced CT scan, in which liver volume assessment was performed when indicated. Magnetic resonance imaging (MRI) and/or positron emission tomography (PET) scan were arranged to confirm doubtful cases. These cases were discussed in a multidisciplinary meeting to decide combined or delayed surgery with or without pre-operativechemotherapy. Written informed consent was obtained from all participants. This study was approved by the Research Ethics Committee of Chang Gung Memorial Hospital (IRB No. 201900541B0) and was conducted in accordance with the principles of Declaration of Helsinki and the International Conference on Harmonization for Good Clinical Practice.

Image analysis {#Sec4}
--------------

Preoperative abdominal CT scans were performed on a GE Discovery CT750 HD lightspeed scanner. Evaluation for sarcopenia was performed using CT measures ofmuscle quality-muscledensity (measured in Hounsfield units (HU))as previously described^[@CR19]--[@CR21]^. All measurements and segmentations were done at the level of the inferior endplate of L4 on axial CT images. To measure muscle density, the paraspinal muscles were outlined using a freehand region-of-interest (ROI) tool on a General Electric Picture Archiving and Communicating System (S1000). The total cross-sectional area of bilateral paraspinal, psoas, and abdominal wall muscles at L4 were evaluated on OsiriX imaging software v. 8.0.2 (Pixmeo, Geneva, Switzerland) with the lean muscle threshold set at −29 to 150 HU^[@CR19]--[@CR21]^. The final Hounsfield unit average calculation (HUAC)was the average ofleft HU and right HU to determine the presence or absence of sarcopenia in the study population.

Follow-up {#Sec5}
---------

The regimens of chemotherapy included fluorouracil and leucovorin, combined with irinotecan and/or oxaliplantin, which was currently the standard treatment for CRLM. Follow-up consisted of out patient visits with serum carcinoembryonic antigen (CEA) levels and imagesevery 3 to 6 months after surgery. Overall survival (OS) was defined as the time interval from the date of hepatic resectionto death from any cause or the last follow-up date. Recurrence-free survival (RFS) was defined as the period after hepatic resection to the date when recurrent tumors were diagnosed.

Statistical analysis {#Sec6}
--------------------

Continuous data were presented as mean ± standard deviation and compared by using Student's *t* test. Categorical variables were expressed as number (percentage) and analyzed by using the χ^2^ or Fisher's exact test depending on the size of the sample. A receiver-operating characteristic (ROC) curve was used to determine the best cutoff of HUAC scorebased on the Youden index. Kaplan--Meier curves were generated for OS and RFS and the differences of survival rates between groups were compared using the log-rank test. The Cox proportional hazards model was employed for univariate and multivariate analyses. The analysis software used was SPSS for Windows version 18 (SPSS Inc., Chicago, IL, USA). All statistical tests were two-sided and differences were considered significant with a *p* \< 0.05.

Results {#Sec7}
=======

Patient characteristics {#Sec8}
-----------------------

Among the study population, the mean age was 59.5 ± 12.1 years with a range 21--85 years, and 106 of them were male. Sixty-twopatients had solitary tumor whereas 57 had 2--3 tumors, and 63 had more than 3 tumors. Neoadjuvant chemotherapy was given in 35 of 182 patients (19.2%), and 166(91.2%) patients received adjuvant chemotherapy after hepatic resection (Table [1](#Tab1){ref-type="table"}).Table 1Baseline characteristics of the study cohort.Age (years)59.5 ± 12.1Gender Male/Female106/76Body mass index (kg/m^2^)24.3 ± 3.6Type 2 DM (%)40 (22%)Synchronous(%)119 (65%)**Chemotherapy**Neoadjuvant/adjuvant/both35/166/28**Primary tumor site\***C/A/T/D/S/RS/R5/14/9/18/69/12/55Tumor stage T1/T2/T3/T43/22/73/84Nodal status N0/N1/N254/83/45Main tumor (cm)3.9 ± 2.5Tumor number1/2,3 /\>362/57/63CEA (ng/ml)178 ± 880AST (U/L)29 ± 13ALT (U/L)27 ± 22Albumin (g/dl)4.1 ± 0.4Platelet (10^3^/μL)257 ± 98NLR2.9 ± 2.3^\*^C/A/T/D/S/RS/R: cecum/ascending colon/transverse colon/descending colon/sigmoid colon/recto-sigmoid colon/rectum.Abbreviation: DM, diabetes mellitus; CEA, c*arcinoembryonic antigen*; aspartate aminotransferase; ALT, alanine aminotransferase; NLR, neutrophil-to-lymphocyte ratio.

ROC analysis for HUAC score in the survival status at the 5-year follow-up identified an optimal cutoffat HUAC of 22 HU. At this cutoff, 48 (26.4%) patients were considered sarcopenic. Patients with sarcopenia were older (*p* \< 0.001) and had higher prevalence of diabetics (*p* = 0.004), higher body mass index (BMI) (*p* \< 0.001) and neutrophil-to-lymphocyte ratio (*p* = 0.026) compared to those without sarcopenia (Table [2](#Tab2){ref-type="table"}). Themajor complications were equally common in sarcopenic and non-sarcopenic patients.Table 2Comparison of demographic and clinical characteristics of patients with and without sarcopenia.With SarcopeniaWithout Sarcopenia*p*-valueCase number48134Age (years)66.6 ± 10.257.0 ± 11.7\<0.001Male (%)24(50%)82(61%)0.232Body mass index (kg/m^2^)25.9 ± 4.123.8 ± 3.2\<0.001Type 2 DM (%)18(38%)22(16%)0.004Synchronous (%)27(56%)92(69%)0.157Neoadjuvant chemotherapy10 (21%)25 (19%)0.831Adjuvant chemotherapy43 (90%)123 (92%)0.767Right-sided primary tumor (%)6(13%)22(16%)0.644Tumor stage T3, 4 (%)41(85%)116(87%)0.811Nodal status N2 (%)10 (21%)35(26%)0.560Main tumor (cm)4.1 ± 2.33.8 ± 2.50.453Tumor number \>3 (%)14(29%)49(37%)0.382CEA (ng/ml)356 ± 1412114 ± 5710.102AST (U/L)28 ± 1429 ± 130.575ALT (U/L)22 ± 1229 ± 230.153Albumin (g/dl)3.9 ± 0.84.1 ± 0.50.072Platelet (10^3^/μL)305 ± 124295 ± 1020.601NLR3.5 ± 3.42.7 ± 1.70.026Data are expressed as mean±standard deviation or number (percentage).Abbreviation: DM, diabetes mellitus; CEA, c*arcinoembryonic antigen*; aspartate aminotransferase; ALT, alanine aminotransferase; NLR, neutrophil-to-lymphocyte ratio.

Factors associated with OS {#Sec9}
--------------------------

The mean follow-up was 32.5 ± 25.5 months (range 2--121). The 1-, 3-, and 5-year OS rates of patients were 89%, 63%, and 49%, respectively. Sarcopenia was not a prognostic factor for OS, as the mean OS durations for patients with sarcopenia was 32.3 ± 25.0 months vs. 33.0 ± 27.1 months for those without sarcopenia (Fig. [1](#Fig1){ref-type="fig"}).Figure 1Kaplan-Meier curves for overall survival. Significance was not found between patients with and without sarcopenia(*p* = 0.446).

Univariate analyses showed significant associations of unfavourable OS were multinodularity (\>3) (*p* \< 0.001), main tumor size (≥3 cm) (*p* = 0.023), blood loss (≥300 cc) (*p* = 0.003), CEA level (≥20 ng/ml) (*p* = 0.046) and platelet count (*p* = 0.016). By multivariate Cox proportional hazards model of factors with p \< 0.2 in univariate analyses, multinodularity (hazard ratio (HR) 2.736; 95% confidence interval (CI), 1.631--4.589; *p* \< 0.001), high CEA level (≥20 ng/ml) (HR 1.793; 95% CI, 1.092--2.945; *p* = 0.021) and blood loss (≥300 cc) (HR 1.793; 95% CI, 1.084--2.964; *p* = 0.023) were independent factors for OS (Table [3](#Tab3){ref-type="table"}).Table 3Univariate and stepwise multivariate analyses of factors associated with overall survival.ComparisonUnivariate analysesStepwise multivariate analysesHR (95% CI)*p*-valueHR (95% CI)*p*-valueAge (years)≥60 vs. \<600.785 (0.483--1.276)0.328GenderMale vs. Female1.132 (0.694--1.849)0.619BMI(kg/m^2^)≥25 vs. \<250.683 (0.410--1.135)0.141DMYes vs. No1.365 (0.785--2.374)0.270SarcopeniaYes vs. No1.226 (0.725--2.073)0.447SynchronousYes vs. No0.911 (0.545--1.522)0.722Neoadjuvant chemotherapyYes vs. No1.116 (0.596--2.092)0.731Adjuvant chemotherapyYes vs. No1.303 (0.522--3.250)0.571Blood loss (cc)≥300 vs. \<3002.116 (1.293--3.461)0.0031.793(1.084--2.964)0.023CEA (ng/ml)≥20 vs. \<201.639 (1.008--2.663)0.0461.793 (1.092--2.945)0.021Primary tumor siteright vs. left1.530 (0.775--3.021)0.220Tumor stageT3,4 vs. 21.305 (0.622--2.735)0.481Nodal statusN2 vs. N0, 11.639 (0.981--2.739)0.059Main tumor (cm)\>3 vs. ≤31.783 (1.085--2.930)0.023Tumor number\>3 vs. ≤32.733 (1.675--4.459)\<0.0012.736 (1.631--4.589)\<0.001AST (U/L)per 1 U/L increase1.016 (0.999--1.032)0.068ALT (U/L)per 1 U/L increase1.007 (0.992--1.022)0.361Albumin (g/dl)per 1 g/dl increase0.744 (0.533--1.038)0.082Platelet (10^3^/μL)per 10^3^/μL increase1.003 (1.001--1.005)0.016NLR \> 3 vs. ≤31.055 (0.608--1.830)0.849Abbreviation: HR, hazard ratio; CI, confidence interval; DM, diabetes mellitus; CEA, carcinoembryonic antigen;aspartate aminotransferase; ALT, alanine aminotransferase; NLR, neutrophil-to-lymphocyte ratio.

In subgroup analyses, sarcopenia was a significant factor of poor OS in the patients with multinodularity (*p* = 0.001) (Fig. [2](#Fig2){ref-type="fig"}). In contrast, there were no associations of sarcopenia with OS in other subgroup analyses, such as age, gender, diabetes, tumor size, etc. Table [4](#Tab4){ref-type="table"} shows thefactors associated with OS in subgroup patients with multiple CRLM. Sarcopenia was the significant factor associated with poor OS in the patients with multiple CRLM by univariate (*p* = 0.002) and multivariate analyses(HR 3.571; 95% CI, 1.508--8.403; *p* = 0.004).Figure 2Kaplan-Meier curves for overall survival in subgroup patients. Sarcopenia was a significant factor of poor OS in the patients withmultinodularity (*p* = 0.001).Table 4Factors associated with overall survival in subgroup patients with multiple CRLM.ComparisonUnivariate analysesStepwise multivariate analysesHR (95% CI)*p*-valueHR (95% CI)*p*-valueAge (years)≥60 vs. \<600.592 (0.291--1.202)0.147GenderMale vs. Female1.151 (0.563--2.352)0.701BMI (kg/m^2^)≥25 vs. \<251.373 (0.672--2.806)0.384DMYes vs. No1.078 (0.515--2.258)0.842SarcopeniaYes vs. No3.322 (1.585--6.993)0.0023.571 (1.508--8.403)0.004SynchronousYes vs. No1.866 (0.755--4.610)0.177Neoadjuvant chemotherapyYes vs. No1.226 (0.589--2.551)0.585Adjuvant chemotherapyYes vs. No0.298 (0.088--1.008)0.051Blood loss (cc)≥300 vs. \<3001.940 (0.956--3.936)0.067CEA (ng/ml)≥ 10 vs. \<101.627 (0.808--3.273)0.173Primary tumor siteright vs. left1.699 (0.645--4.475)0.283Tumor stageT3,4 vs. 2,11.147 (0.348--3.787)0.821Nodal statusN2 vs. N0, 11.124 (0.536--2.353)0.757Main tumor (cm)\>3 vs. ≤31.822 (0.865--3.836)0.114AST (U/L)per 1 U/L increase1.000 (0.979--1.021)0.966ALT (U/L)per 1 U/L increase0.998 (0.982--1.014)0.776Albumin (g/dl)per 1 g/dl increase0.356 (0.115--1.098)0.072Platelet (10^3^/μL)per 10^3^/μL increase1.002 (0.997--1.008)0.353NLR \> 3 vs. ≤31.234 (0.563--2.703)0.599Abbreviation: CRLM, colorectal liver metastasis; HR, hazard ratio; CI, confidence interval; DM, diabetes mellitus; CEA, carcinoembryonic antigen; aspartate aminotransferase; ALT, alanine aminotransferase; NLR, neutrophil-to-lymphocyte ratio.

Factors associated with RFS {#Sec10}
---------------------------

The 1-, 3-, and 5-year RFS rates of patients were 59%, 33%, and 25%, respectively. Sarcopenia was not a significant factor for RFS (Fig. [3](#Fig3){ref-type="fig"}). As shown in Table [5](#Tab5){ref-type="table"}, multinodularity (*p* \< 0.001), main tumor size (≥3 cm) (*p* = 0.017), male gender (*p* = 0.035) and higher pretreatment serum levels of aspartate aminotransferase (AST) (*p* = 0.004) and alanine aminotransferase (ALT) (*p* = 0.008) were associated with shorter RFS. Multivariate Cox's regression analyses showed that multinodularity (\>3) (HR 1.750; 95% CI, 1.066--2.872; *p* = 0.027), high AST level (HR 1.024; 95% CI, 1.003--1.046; *p* = 0.025) and male gender (HR 1.688; 95% CI, 1.036--2.748; *p* = 0.035) were independent factors (Table [5](#Tab5){ref-type="table"}).Figure 3Kaplan-Meier curves for recurrence-free survival. Significance was not found between patients with and without sarcopenia(p = 0.811).Table 5Univariate and stepwise multivariate analyses of factors associated with recurrence -free survival.ComparisonUnivariate analysesStepwise multivariate analysesHR (95% CI)*p*-valueHR (95% CI)*p*-valueAge (years)≥60 vs. \<600.897 (0.617--1.305)0.571GenderMale vs. Female1.519 (1.030--2.239)0.0351.688 (1.036--2.748)0.035BMI (kg/m2)≥25 vs. \<250.937 (0.637--1.377)0.739DMYes vs. No1.073 (0.681--1.689)0.762SarcopeniaYes vs. No1.054 (0.683--1.628)0.811SynchronousYes vs. No1.129 (0.760--1.678)0.548Neoadjuvant chemotherapyYes vs. No0.854 (0.521--1.401)0.533Adjuvant chemotherapyYes vs. No1.814 (0.839--3.919)0.130Blood loss (cc)≥300 vs. \<3001.451 (0.987--2.134)0.058CEA (ng/ml)≥20 vs. \<201.374 (0.931--2.029)0.110Primary tumor siteright vs. left0.704 (0.394--1.260)0.238Tumor stageT3,4 vs. 2,11.538 (0.844--2.803)0.160Nodal statusN2 vs. N0, 11.259 (0.827--1.918)0.283Main tumor (cm)\>3 vs. ≤31.588 (1.086--2.322)0.017Tumor number\>3 vs. ≤32.222 (1.505--3.281)\<0.0011.750 (1.066--2.872)0.027AST (U/L)per 1 U/L increase1.021 (1.006--1.035)0.0041.024 (1.003--1.046)0.025ALT (U/L)per 1 U/L increase1.016 (1.004--1.027)0.008Albumin (g/dl)per 1 g/dl increase1.025 (0.738--1.423)0.883Platelet (10^3^/μL)per 10^3^/μL increase0.999 (0.998--1.001)0.594NLR\>3 vs. ≤30.984 (0.651--1.488)0.939Abbreviation: HR, hazard ratio; CI, confidence interval; DM, diabetes mellitus; CEA, carcinoembryonic antigen.aspartate aminotransferase; ALT, alanine aminotransferase; NLR, neutrophil-to-lymphocyte ratio.

Discussion {#Sec11}
==========

This present study showed that preoperative sarcopenia was not associated with long-term survival in a homogeneous population of CRLM undergoing hepatic resection. Sarcopeniawas not a significant risk factor of OS and RFS in our study population. However, our study provided the first evidence that sarcopenia predicted worse OS in the subgroup patients with multinodularity (\>3).

A number of clinicopathological factors have been constantly reported as having prognostic value following hepatectomy of CRLM^[@CR8],[@CR9],[@CR22]--[@CR24]^. In this study, we demonstrated that multinodularity (\>3), high CEA level (≥20 ng/ml) and blood loss (\>300 cc) were independent factors associated with poorer OS. Our data were compatible with those reported in most studies^[@CR8],[@CR9],[@CR22]--[@CR24]^, showing that the number of liver metastaseswas the most important negative predictor not only for OS but also for RFS. In contrast, the location of primary tumoremerging as an important prognostic factor was not significant in our study^[@CR25]^. This could be attributed to the small case number of right sided cancer in this series.

Recently, the use of sarcopenia to predict outcomes in cancer patients has attracted more attention, including those with CRLM undergoing hepatic resection. Previous studies demonstrated that sarcopenia increased risk of post-operative morbidity and longer hospital stay as well as readmission ratesafter partial liver resection for CRLM^[@CR15],[@CR18]^. On the contrary, sarcopeniadid not seemto impact long-term outcomes in their patients. Our data, in line with their results, showed that sarcopenia was not a significant risk factor of OS and RFS. Moreover, considering the greater impact of other stronger risk factors such as tumor number, we therefore analyzed the effect of sarcopenia on the subgroups of our patients. Interestingly, we found that sarcopenia was significantly predictive of worse OS in the patients with multiple CRLM. Based on our findings, we recommended that patients with multiple (\>3) CRLM and combined sarcopenia, hepatic resection might be considered cautiously due to limited survival. However, further studies with longer follow-up periods should be necessary to confirm our observation.

In our study population, sarcopenia was associated with advanced age, diabeticsand obesity. Although these results were discrepant with other findings^[@CR15],[@CR26]^, our data were consistent with a recent report showing that age and obesity were found to be independently associated with sarcopenia in patients undergoing liver transplant evaluation^[@CR27]^. Previous studies have reported that patients with sarcopenic obesity had worse survival in hepatocellular carcinoma receiving hepatectomy or after living donor liver transplantation^[@CR28]--[@CR31]^. While our data in accordance with a recent study showed that sarcopenicobesity was not a prognostic factor in patientsundergoingliver resection for CRLM^[@CR32]^.

This present study is limited based on its retrospective nature and thus there may have been selection bias. Moreover, we believed that the bias was smallbecause patientswere followed regularly with clinical and laboratory assessment using CEA and imaging studies every 3 to 6 months. Secondly, we defined obesity as BMI≧25 kg/m^2^ by clinical diagnosis, whereas other studies assessed the visceral adipose tissueusing CT evaluation^[@CR18],[@CR29]^. However, a previous study has showna close positive correlation of BMI with visceral adipose tissue, andobesity is adequately specified as a BMI≧25 kg/m^2^ in Asian populations^[@CR33]^. Third, the recent novel mutational molecular markers, such as microsatellite instability, BRAF, and KRAS/NRAS and combination mutations which conferred poorer outcomeswere not available in our study^[@CR24]^. It willbe interesting to determine the association of molecular markerswith long-term prognosisin patients with CRLM after partial hepatectomy in further studies.

In conclusion, in spite of no significance in long-term outcomes in whole cohort, sarcopenia is associated with an increased survival risk of patients with multiple CRLM undergoing hepatic resection. Assessment of preoperative sarcopenia provides an easy tool for selection of CRLM patients for liver resection. Further large-scale and multicenter studies are stillneeded to clarify these issues.
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